10:59 AM EDT, 05/06/2025 (MT Newswires) -- Heron Therapeutics ( HRTX ) said Tuesday it reached a settlement agreement with Viatris' ( VTRS ) Mylan Pharmaceuticals to resolve patent litigation over the Cinvanti and Aponvie injectable emulsions.

Under the deal, Heron granted Mylan a license to market generic versions of Cinvanti and Aponvie in the US beginning June 1, 2032.

In connection with the settlement, Heron and Mylan will ask the US District Court for the District of Delaware to dismiss the pending litigations, Heron said.

The company said it initiated the litigations in response to what it described as Mylan's abbreviated new drug applications seeking the US Food and Drug Administration's approval of generic Cinvanti and Aponvie versions before the expiration of the Heron patents in 2035.

Heron shares rose nearly 14% in recent trading.

Price: 2.43, Change: +0.30, Percent Change: +13.85